Lindagan, Sayba M.
HRN: 07-62-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/31/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/31/2025
10/31/2025
IV
300mg
Once
COMPLICATED UTI
Checking Final Appropriateness
Indication: Empiric Then Culture-directed Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes